

## Supporting Information

### **Discovery of 3,6-Disubstituted Pyridazines as a Novel Class of Anticancer Agents Targeting Cyclin-Dependent Kinase 2: Synthesis, Biological Evaluation and In Silico Insights**

Ahmed Sabt, Wagdy M. Eldehna<sup>\*</sup>, Tarfah Al-Warhi, Ohoud J. Alotaibi, Mahmoud M. Elaasser, Howayda Suliman, Hatem A. Abdel-Aziz

## Tables of Contents

1.	Characterization of intermediate ( <b>2, 3, 4, 5, 6</b> and <b>13</b> ) and target pyridazines <b>11a-r</b>	3
2.	Anti-proliferative Activity	11
3.	Cell Cycle Analysis	11
4.	AnnexinV-FITC/PI Apoptosis Assay	12
5.	CDK Kinase Inhibitory Activity Statistical Analysis	12
6.	Statistical Analysis	12
7.	Figure S1. Different target classes suggested by SwissTargetPrediction online tool	13
8.	Table S1. Different targets suggested by SwissTargetPrediction online tool	14-18
9.	NMR Spectra	19-68

## 1. Characterization of intermediate (2, 3, 4, 5, 6 and 13) and target pyridazines 11a-r

### Ethyl 2-hydroxy-4-oxo-2-(trifluoromethyl)pentanoate (2)

Yellow oil;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 1.20 (t, 3H,  $J = 7.2$  Hz,  $\text{CH}_3$ ), 2.11 (s, 3H,  $\text{CH}_3$ ), 3.03 (q, 2H,  $J = 17.6$  Hz,  $\text{OCH}_2$ ), 4.19 (brs, 1H, OH), Ha 4.24 (d, 1H,  $J = 2.4$  Hz), Hb 4.26 (d, 1H,  $J = 2.4$  Hz).

### 6-Methyl-4-(trifluoromethyl)pyridazin-3(2H)-one (3)

White crystals (0.27 g, 69%); m.p. 184-185 °C (reported m.p. 187-189 °C [32]);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 2.42 (s, 3H,  $\text{CH}_3$ ), 7.49 (s, 1H, CH), 12.44 (brs, 1H, NH);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)  $\delta$  ppm: 20.67 ( $\text{CH}_3$ ), 116.92 (q,  $J_{\text{C,F}} = 271.4$  Hz,  $\text{CF}_3$ ), 128.90 (q,  $J_{\text{C,F}} = 32.7$  Hz, C4), 132.38 (q,  $J_{\text{C,F}} = 4.6$  Hz, C5), 144.69 (C=N), 157.58 (C=O);  $^{19}\text{F}$  NMR ( $\text{CDCl}_3$ , 376 MHz)  $\delta$  ppm: 67.33 (s, 3F).

### 6-Oxo-5-(trifluoromethyl)-1,6-dihydropyridazine-3-carboxylic acid (4)

White crystals (0.06 g, 54%); m.p. 239-240 °C;  $^1\text{H}$  NMR ( $\text{DMSO-}d_6$ , 400 MHz)  $\delta$  ppm: 3.17 (brs, 1H, NH), 8.20 (s, 1H, CH-pyridazinone), 14.18 (s, 1H, COOH); Analysis for  $\text{C}_6\text{H}_3\text{F}_3\text{N}_2\text{O}_3$  (208), Calcd.: % C, 34.63; H, 1.45; N, 13.46; Found: C, 34.51; H, 1.47; N, 13.52.

### Ethyl 6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazine-3-carboxylate (5)

White solid (3.0 g, 90%); m.p. 147-148 °C;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 1.35 (t, 3H,  $J = 6.8$  Hz,  $\text{CH}_3$ ), 4.39 (q, 2H,  $J = 7.2$  Hz,  $\text{CH}_2$ ), 7.9 (brs, 1H, NH), 8.18 (s, 1H, CH-pyridazine), 12.26 (brs, 1H, NH); Analysis for  $\text{C}_8\text{H}_7\text{F}_3\text{N}_2\text{O}_3$  (236), Calcd.: % C, 40.69; H, 2.99; N, 11.86; Found: C, 40.56; H, 3.00; N, 11.91.

### Ethyl 6-chloro-5-(trifluoromethyl) pyridazine-3-carboxylate (6)

Yellow liquid (1.1 g, 51%);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 1.49 (t, 3H,  $J = 7.2$  Hz,  $\text{CH}_3$ ), 4.57 (q, 2H,  $J = 7.2$  Hz,  $\text{OCH}_2$ ), 8.44 (s, 1H, CH-pyridazine);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)  $\delta$  ppm: 14.09 ( $\text{CH}_3$ ), 63.42 ( $\text{OCH}_2$ ), 116.59 (q,  $J_{\text{C,F}} = 273$  Hz,  $\text{CF}_3$ ), 126.31 (q,  $J_{\text{C,F}}$ )

= 4.7 Hz, C4), 128.86 (q,  $J_{(C,F)} = 35.6$  Hz, C5), 151.45 (C=N), 154.95 (C-Cl), 162.16 (C=O); Analysis for  $C_8H_6ClF_3N_2O_2$  (254), Calcd.: C, 37.74; H, 2.38; N, 11.00; Found: C, 37.82; H, 2.36; N, 10.95.

### **Ethyl 6-morpholino-5-(trifluoromethyl)pyridazine-3-carboxylate (13)**

Yellow oil (0.0476 g, 70%);  $^1H$  NMR ( $CDCl_3$ , 400 MHz)  $\delta$  ppm: 1.37 (t, 3H,  $J = 7.2$  Hz,  $CH_3$ ), 3.68 (t, 4H,  $J = 4.4$  Hz,  $2 \times CH_2-N$ ), 3.78 (t, 4H,  $J = 5.2$  Hz,  $2 \times CH_2-O$ ), 4.41 (q, 2H,  $J = 7.2$  Hz,  $OCH_2$ ), 8.11 (s, 1H, CH-pyridazine); Analysis for  $C_{12}H_{14}F_3N_3O_3$  (305), Calcd.: C, 47.22; H, 4.62; N, 13.77; Found: C, 47.40; H, 4.59; N, 13.93.

### **Target pyridazine derivatives (11a-r)**

N-(Adamantan-2-yl)-6-((2-hydroxyethyl)amino)-5-(trifluoromethyl)pyridazine-3-carboxamide (11a)

Pale yellow crystals; Yield (63%); m.p. 202-203 °C;  $^1H$  NMR ( $CDCl_3$ , 400 MHz)  $\delta$  ppm: 1.59 (d,  $J = 12.8$  Hz, 2H), 1.70 (s, 2H), 1.83 (s, 6H), 1.86 (d,  $J = 13.6$  Hz, 2H), 1.96 (brs, 2H), 2.60 (brs, 1H, OH), 3.83 (t, 2H,  $J = 5.2$  Hz,  $CH_2-NH$ ), 3.87 (t, 2H,  $J = 4.8$  Hz,  $CH_2-OH$ ), 4.17 (d, 1H,  $J = 8.4$  Hz, 1H-adamantyl), 5.71 (brs, 1H, NH), 8.14 (s, 1H, CH-pyridazine), 8.18 (d, 1H,  $J = 8.4$  Hz, NH);  $^{13}C$  NMR ( $CDCl_3$ , 100 MHz)  $\delta$  ppm: 26.10, 26.20, 30.85 (2xC), 31.07 (2xC), 36.10 (2xC), 36.49, 43.45 ( $CH_2-NH$ ), 52.54 (NH-C-adamantyl), 60.23 ( $CH_2-OH$ ), 113.20 (q,  $J_{(C,F)} = 33.7$  Hz, C5), 117.56 (q,  $J_{(C,F)} = 272$  Hz,  $CF_3$ ), 122.67 (q,  $J_{(C,F)} = 5.0$  Hz, C4), 144.37 (C=N), 153.84 (C=O), 160.22 (-N-C=N); Analysis for  $C_{18}H_{23}F_3N_4O_2$  (384), Calcd.: C, 56.24; H, 6.03; N, 14.58; Found: C, 56.47; H, 5.98; N, 14.64.

N-(Adamantan-2-yl)-6-(butylamino)-5-(trifluoromethyl)pyridazine-3-carboxamide (11b)

Yellow solid; Yield (72%); m.p. 110-111 °C;  $^1H$  NMR ( $CDCl_3$ , 400 MHz)  $\delta$  ppm: 0.89 (t, 3H,  $J = 7.2$  Hz,  $CH_3$ ), 1.34-1.43 (m, 2H,  $CH_2$ ), 1.55 (d,  $J = 13.6$  Hz, 2H), 1.62-1.70 (m, 4H), 1.83 (s, 6H), 1.88 (d,  $J = 13.2$  Hz, 2H), 1.97 (s, 2H), 3.64 (d, 2H,  $J = 4.0$  Hz,  $CH_2-NH$ ), 4.18 (d, 1H,  $J = 8.4$  Hz, 1H-adamantyl), 5.11 (brs, 1H, NH), 8.12 (s, 1H, CH-pyridazine), 8.19 (d, 1H,  $J = 8.0$  Hz, NH-C=O);  $^{13}C$  NMR ( $CDCl_3$ , 100 MHz)  $\delta$  ppm: 12.74 ( $CH_3$ ), 19.07,

26.14, 26.22, 30.07, 30.85 (2xC), 31.09 (2xC), 36.13 (2xC), 36.52, 41.13 (CH<sub>2</sub>-NH), 52.47 (NH-C-adamantyl), 112.58 (q,  $J_{(C,F)} = 33.5$  Hz, C5), 120.46 (q,  $J_{(C,F)} = 271.5$  Hz, CF<sub>3</sub>), 122.45 (q,  $J_{(C,F)} = 5.0$  Hz, C4), 144.05 (C=N), 153.52 (C=O), 160.31 (-N-C=N); Analysis for C<sub>20</sub>H<sub>27</sub>F<sub>3</sub>N<sub>4</sub>O (396), Calcd.: C, 60.59; H, 6.86; N, 14.13; Found: C, 60.67; H, 6.91; N, 14.05.

N-(Adamantan-2-yl)-6-(cyclopentylamino)-5-(trifluoromethyl)pyridazine-3-carboxamide (11c)

White solid; Yield (36%); m.p. 135-136 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  ppm: 1.44-1.52 (m, 2H, CH<sub>2</sub>), 1.58 (d, 2H,  $J = 13.2$  Hz), 1.63-1.69 (m, 6H), 1.83 (s, 6H), 1.88 (d,  $J = 13.2$  Hz, 2H), 1.96 (s, 2H), 2.11-2.19 (m, 2H, CH<sub>2</sub>), 4.18 (d, 1H,  $J = 8.0$  Hz, 1H-adamantyl), 4.57-4.65 (m, 1H, CH-cyclopentyl), 5.05 (d, 1H,  $J = 6.0$  Hz, NH), 8.11 (s, 1H, CH-pyridazine), 8.19 (d, 1H,  $J = 8.4$  Hz, NH); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  ppm: 22.70 (2xC), 26.15, 26.23, 30.84 (2xC), 31.09 (2xC), 32.25 (2xC), 36.14 (2xC), 36.53, 52.49 (CH-cyclopentyl), 52.83 (NH-C-adamantyl), 112.59 (q,  $J_{(C,F)} = 33.4$  Hz, C5), 117.74 (q,  $J_{(C,F)} = 271.6$  Hz, CF<sub>3</sub>), 122.44 (q,  $J_{(C,F)} = 5.1$  Hz, C4), 143.92 (C=N), 153.22 (C=O), 160.35 (-N-C=N); Analysis for C<sub>21</sub>H<sub>27</sub>F<sub>3</sub>N<sub>4</sub>O (408), Calcd.: C, 61.75; H, 6.66; N, 13.72; Found: C, 61.61; H, 6.63; N, 13.68.

N-(Adamantan-2-yl)-6-morpholino-5-(trifluoromethyl)pyridazine-3-carboxamide (11d)

White solid; Yield (50%); m.p. 177-178 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  ppm: 1.60 (d,  $J = 12.8$  Hz, 2H), 1.70 (s, 2H), 1.84 (s, 6H), 1.87 (d,  $J = 13.6$  Hz, 2H), 1.98 (s, 2H), 3.57 (t, 4H,  $J = 4.0$  Hz, 2xCH<sub>2</sub>-N), 3.79 (t, 4H,  $J = 4.4$  Hz, 2xCH<sub>2</sub>-O), 4.20 (d, 1H,  $J = 8.0$  Hz, 1H-adamantyl), 8.24 (d, 1H,  $J = 8.0$  Hz, NH-C=O), 8.28 (s, 1H, CH-pyridazine); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  ppm: 26.10, 26.20, 30.86 (2xC), 31.08 (2xC), 36.09 (2xC), 36.48, 49.32 (2xCH<sub>2</sub>-N), 52.60 (adamantyl-C-NH), 65.57 (2xCH<sub>2</sub>-O), 117.63 (q,  $J_{(C,F)} = 272.3$  Hz, CF<sub>3</sub>), 117.83 (q,  $J_{(C,F)} = 34.1$  Hz, C5), 124.98 (q,  $J_{(C,F)} = 5.2$  Hz, C4), 146.54 (C=N), 157.54 (C=O), 159.75 (-N-C=N); Analysis for C<sub>20</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (410), Calcd.: C, 58.53; H, 6.14; N, 13.65; Found: C, 58.45; H, 6.15; N, 13.69.

N-(Adamantan-2-yl)-5-(trifluoromethyl)-6-((2(trifluoromethyl)benzyl)amino)pyridazine-3-carboxamide (11e)

White solid; Yield (41%); m.p. 150-151 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  ppm: 1.59 (d,  $J$  = 12.4 Hz, 2H), 1.70 (s, 2H), 1.83 (s, 6H), 1.87 (d,  $J$  = 13.2 Hz, 2H), 1.97 (brs, 2H), 4.18-4.20 (m, 1H, 1H-adamantyl), 5.09 (d,  $J$  = 5.6 Hz, 2H, CH<sub>2</sub>-NH), 5.50 (t-like, 1H,  $J$  = 5.6 Hz, NH), 7.34 (t, 1H,  $J$  = 7.6 Hz, C5-Ar), 7.45 (t, 1H,  $J$  = 7.6 Hz, C4-Ar), 7.53 (d, 1H,  $J$  = 8.00 Hz, C6-Ar), 7.63 (d, 1H,  $J$  = 8.00 Hz, C3-Ar), 8.18 (s, 1H, CH-pyridazine), 8.20 (d, 1H,  $J$  = 3.6 Hz, NH-CO); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  ppm: 26.11, 26.20, 30.85 (2xC), 31.05 (2xC), 31.09, 36.11 (2xC), 36.49, 40.51, 41.69 (CH<sub>2</sub>-NH), 52.57 (NH-C-adamantyl), 113.03 (q,  $J_{(C,F)}$  = 33.6 Hz, C5), 120.29 (q,  $J_{(C,F)}$  = 271.9 Hz, CF<sub>3</sub>-pyridazine), 122.20 (q,  $J_{(C,F)}$  = 256.5 Hz, CF<sub>3</sub>-Ar), 122.72 (q,  $J_{(C,F)}$  = 4.9 Hz, C4), 124.49 (q,  $J_{(C,F)}$  = 26.7 Hz, C2-Ar), 125.38 (q,  $J_{(C,F)}$  = 5.8 Hz, C3-Ar), 127.04 (C5-Ar), 129.19 (C4-Ar), 131.40 (C6-Ar), 134.55 (C1-Ar), 144.92 (C=N), 153.16 (C=O), 160.11 (-N-C=N); Analysis for C<sub>24</sub>H<sub>24</sub>F<sub>6</sub>N<sub>4</sub>O (498), Calcd.: C, 57.83; H, 4.85; N, 11.24; Found: C, 57.94; H, 4.88; N, 11.19.

N-(tert-Butyl)-6-(cyclopentylamino)-5-(trifluoromethyl)pyridazine-3-carboxamide (11f)

Brown solid; Yield (71%); m.p. 62-63 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  ppm: 1.40 (s, 9H, 3xCH<sub>3</sub>), 1.43-1.51 (m, 2H, CH<sub>2</sub>), 1.58-1.72 (m, 4H, 2xCH<sub>2</sub>), 2.11-2.18 (m, 2H, CH<sub>2</sub>), 4.53-4.61 (m, 1H, CH-cyclopentyl), 5.05 (brs, 1H, NH), 7.76 (brs, 1H, NH-C=O), 8.10 (s, 1H, CH-pyridazine); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  ppm: 22.72 (2xCH<sub>2</sub>), 27.78 (3xCH<sub>3</sub>), 32.22 (2xCH<sub>2</sub>-CH), 50.32 (NH-C-t-butyl), 52.87 (CH-NH), 112.68 (q,  $J_{(C,F)}$  = 33.6 Hz, C5), 120.43 (q,  $J_{(C,F)}$  = 271.4 Hz, CF<sub>3</sub>), 122.10 (q,  $J_{(C,F)}$  = 5.0 Hz, C4), 144.20 (C=N), 153.11 (C=O), 160.40 (-N-C=N); Analysis for C<sub>15</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O (330), Calcd.: C, 54.54; H, 6.41; N, 16.96; Found: C, 54.72; H, 6.38; N, 17.05.

N-(tert-Butyl)-6-morpholino-5-(trifluoromethyl)pyridazine-3-carboxamide (11g)

Light yellow solid; Yield (73%); m.p. 121-122 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  ppm: 1.43 (s, 9H, 3xCH<sub>3</sub>), 3.56 (t, 4H,  $J$  = 4.4 Hz, 2xCH<sub>2</sub>-N), 3.79 (t, 4H,  $J$  = 4.8 Hz, 2xCH<sub>2</sub>-O), 7.79 (brs, 1H, NH), 8.27 (s, 1H, CH-pyridazine); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  ppm: 27.74 (3xCH<sub>3</sub>), 49.30 (2xCH<sub>2</sub>-N), 50.53 (C-NH), 65.55 (2xCH<sub>2</sub>-O), 117.61 (q,  $J_{(C,F)}$  = 272.4 Hz, CF<sub>3</sub>), 117.92 (q,  $J_{(C,F)}$  = 34.1 Hz, C5), 124.66 (q,  $J_{(C,F)}$  = 5.2 Hz, C4), 146.86 (C=N), 157.44 (C=O), 159.79 (-N-C=N); Analysis for C<sub>14</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (332), Calcd.: C, 50.60; H, 5.76; N, 16.86; Found: C, 50.49; H, 5.77; N, 16.90.

N-(tert-Butyl)-5-(trifluoromethyl)-6-((2-(trifluoromethyl) benzyl) amino)pyridazine-3-carboxamide (11h)

White solid; Yield (43%); m.p. 132-133 °C;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 1.40 (s, 9H, 3x $\text{CH}_3$ ), 5.07 (d, 2H,  $J = 6.0$  Hz,  $\text{CH}_2\text{-NH}$ ), 5.51 (t-like, 1H,  $J = 6.0$  Hz, NH), 7.33 (t, 1H,  $J = 7.6$  Hz, C5-Ar), 7.44 (t, 1H,  $J = 7.6$  Hz, C4-Ar), 7.51 (d, 1H,  $J = 7.6$  Hz, C6-Ar), 7.62 (d, 1H,  $J = 7.6$  Hz, C3-Ar), 7.72 (brs, 1H, NH-C=O), 8.16 (s, 1H, CH-pyridazine);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)  $\delta$  ppm: 27.75 (3x $\text{CH}_3$ ), 41.66 ( $\text{CH}_2\text{-NH}$ ), 50.42 (NH-C-t-butyl), 113.13 (q,  $J_{(\text{C,F})} = 33.6$  Hz, C5), 120.28 (q,  $J_{(\text{C,F})} = 271.8$  Hz,  $\text{CF}_3\text{-pyridazine}$ ), 122.05 (q,  $J_{(\text{C,F})} = 272.1$  Hz,  $\text{CF}_3\text{-Ar}$ ), 122.42 (q,  $J_{(\text{C,F})} = 4.8$  Hz, C4), 125.37 (q,  $J_{(\text{C,F})} = 5.7$  Hz, C3-Ar), 127.26 (q,  $J_{(\text{C,F})} = 30.5$  Hz, C2-Ar), 126.97 (C6-Ar), 129.06 (C4-Ar), 131.34 (C5-Ar), 134.58 (C1-Ar), 145.26 (C=N), 153.06 (C=O), 160.15 (-N-C=N); Analysis for  $\text{C}_{18}\text{H}_{18}\text{F}_6\text{N}_4\text{O}$  (420), Calcd.: C, 51.43; H, 4.32; N, 13.33; Found: C, 51.50; H, 4.29; N, 13.31.

N-Butyl-6-morpholino-5-(trifluoromethyl)pyridazine-3-carboxamide (11i)

Brown oil; Yield (69%);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 0.86 (t, 3H,  $J = 7.2$  Hz,  $\text{CH}_3$ ), 1.31-1.40 (m, 2H,  $\text{CH}_2$ ), 1.51-1.59 (m, 2H,  $\text{CH}_2$ ), 3.41 (q, 2H,  $J = 6.8$  Hz,  $\text{CH}_2\text{-NH}$ ), 3.57 (t, 4H,  $J = 4.8$  Hz, 2x $\text{CH}_2\text{-N}$ ), 3.79 (t, 4H,  $J = 4.8$  Hz, 2x $\text{CH}_2\text{-O}$ ), 7.83 (t-like,  $J = 4.0$  Hz, 1H, NH), 8.27 (s, 1H, CH-pyridazine);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)  $\delta$  ppm: 12.09 ( $\text{CH}_3$ ), 19.03, 30.53 ( $\text{CH}_2$ ), 38.30 ( $\text{CH}_2\text{-NH}$ ), 49.26 (2x $\text{CH}_2\text{-N}$ ), 65.56 (2x $\text{CH}_2\text{-O}$ ), 117.66 (q,  $J_{(\text{C,F})} = 34.2$  Hz, C5), 120.35 (q,  $J_{(\text{C,F})} = 272.5$  Hz,  $\text{CF}_3$ ), 124.93 (q,  $J_{(\text{C,F})} = 5.2$  Hz, C4), 146.14, 157.46 (C=O), 160.73 (-N-C=N); Analysis for  $\text{C}_{14}\text{H}_{19}\text{F}_3\text{N}_4\text{O}_2$  (332), Calcd.: C, 50.60; H, 5.76; N, 16.86; Found: C, 50.77; H, 5.78; N, 16.93.

6-((2-Hydroxyethyl)amino)-N-((tetrahydro-2H-pyran-4-yl)methyl)-5-(trifluoromethyl)pyridazine-3-carboxamide (11j)

White solid; Yield (79%); m.p. 95-96 °C;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 1.24-1.37 (m, 2H), 1.59 (d, 2H,  $J = 12.8$  Hz), 1.76-1.82 (m, 1H, CH), 3.27-3.34 (m, 4H, 2x $\text{CH}_2\text{-O}$ ), 3.83 (t, 2H,  $J = 4.4$  Hz,  $\text{CH}_2\text{-NH}$ ), 3.87 (t, 2H,  $J = 4.8$  Hz,  $\text{CH}_2\text{-OH}$ ), 3.91 (d, 2H,  $J = 3.2$  Hz), 5.74 (brs, 1H, NH), 7.89 (t-like, 1H,  $J = 4.4$  Hz, NH-C=O), 8.12 (s, 1H, CH-pyridazine);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)  $\delta$  ppm: 29.57 (2x $\text{CH}_2$ ), 34.47 (CH), 43.44, 44.10

(CH<sub>2</sub>-NH), 60.12 (CH<sub>2</sub>-O), 66.54 (2xCH<sub>2</sub>-O), 113.16 (q,  $J_{(C,F)} = 33.8$  Hz, C5), 120.23 (q,  $J_{(C,F)} = 271.7$  Hz, CF<sub>3</sub>), 122.67 (q,  $J_{(C,F)} = 5.1$  Hz, C4), 143.82 (C=N), 153.90 (C=O), 161.43 (-N-C=N); Analysis for C<sub>14</sub>H<sub>19</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (348), Calcd.: C, 48.27; H, 5.50; N, 16.08; Found: C, 48.16; H, 5.49; N, 16.11.

6-(Butylamino)-N-((tetrahydro-2*H*-pyran-4-yl)methyl)-5-(trifluoromethyl)pyridazine-3-carboxamide (11k)

Yellow oil; Yield (48%); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  ppm: 0.89 (t, 3H,  $J = 7.2$  Hz, CH<sub>3</sub>), 1.26-1.43 (m, 4H), 1.59-1.69 (m, 4H), 1.75-1.83 (m, 1H, CH), 3.27 (m, 2H), 3.33 (t, 2H,  $J = 6.4$  Hz), 3.64 (q, 2H,  $J = 6.8$  Hz, CH<sub>2</sub>-NH), 3.89 (dd, 2H,  $J = 3.2, 11.2$  Hz, 2xCH<sub>2</sub>-N), 5.17 (brs, 1H, NH), 7.89 (t-like, 1H,  $J = 5.2$  Hz, NH-C=O), 8.11 (s, 1H, CH-pyridazine); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  ppm: 13.22 (CH<sub>3</sub>), 29.57 (2xCH<sub>2</sub>), 34.45, 34.51, 43.44, 44.07 (CH<sub>2</sub>-NH), 46.34, 66.55 (2xCH<sub>2</sub>-O), 112.50 (q,  $J_{(C,F)} = 33.5$  Hz, C5), 120.37 (q,  $J_{(C,F)} = 271.7$  Hz, CF<sub>3</sub>), 122.44 (q,  $J_{(C,F)} = 4.9$  Hz, C4), 143.55 (C=N), 153.46 (C=O), 161.49 (-N-C=N); Analysis for C<sub>16</sub>H<sub>23</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (360), Calcd.: C, 53.33; H, 6.43; N, 15.55; Found: C, 53.48; H, 6.44; N, 15.59.

6-((Cyclopropylmethyl)amino)-N-((tetrahydro-2*H*-pyran-4-yl)methyl)-5-(trifluoromethyl)pyridazine-3-carboxamide (11l)

Yellow oil; Yield (38%); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  ppm: 0.25 (q-like, 2H,  $J = 4.8$  Hz), 0.53 (q-like, 2H,  $J = 5.6$  Hz), 1.10-1.17 (m, 1H), 1.26-1.37 (m, 2H), 1.59 (d, 2H,  $J = 12.8$  Hz), 1.76-1.80 (m, 1H), 3.27-3.35 (m, 4H, 2xCH<sub>2</sub>-THP), 3.49 (dd, 2H,  $J = 4.8, 6.8$  Hz, CH<sub>2</sub>-NH), 3.85 (dd, 2H,  $J = 2.8, 11.2$  Hz), 5.30 (brs, 1H, NH), 7.90 (t-like, 1H,  $J = 6.4$  Hz, NH-C=O), 8.11 (s, 1H, CH-pyridazine); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  ppm: 12.74, 13.22, 19.06, 29.60 (2xCH<sub>2</sub>), 30.02, 34.51 (CH), 41.12 (CH<sub>2</sub>-NHCO), 44.07 (CH<sub>2</sub>-NH), 66.55 (2xCH<sub>2</sub>-O), 112.53 (q,  $J_{(C,F)} = 33.0$  Hz, C5), 120.23 (q,  $J_{(C,F)} = 271.6$  Hz, CF<sub>3</sub>), 122.67 (q,  $J_{(C,F)} = 5.0$  Hz, C4), 143.45 (C=N), 153.59 (C=O), 161.49 (-N-C=N); Analysis for C<sub>16</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (358), Calcd.: C, 53.63; H, 5.91; N, 15.63; Found: C, 53.71; H, 5.86; N, 15.69.



6-Morpholino-N-((tetrahydro-2H-pyran-4-yl)methyl)-5-(trifluoromethyl)pyridazine-3-carboxamide (11m)

Light Yellow solid; Yield (73%); m.p. 67-68 °C;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 1.27-1.38 (m, 2H), 1.60 (d, 2H,  $J = 11.6$  Hz), 1.77-1.85 (m, 1H, CH), 3.27-3.37 (m, 2H), 3.33 (t, 2H,  $J = 6.4$  Hz), 3.58 (t, 4H,  $J = 4.4$  Hz,  $2\times\text{CH}_2\text{-N}$ ), 3.79 (t, 4H,  $J = 4.8$  Hz,  $2\times\text{CH}_2\text{-O}$ ), 3.89 (dd, 2H,  $J = 3.6$  Hz,  $\text{CH}_2\text{-NH}$ ), 7.94 (t-like, 1H,  $J = 5.6$  Hz,  $\text{NH-C=O}$ ), 8.26 (s, 1H, CH-pyridazine);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 100 MHz)  $\delta$  ppm: 29.59 ( $2\times\text{CH}_2$ ), 34.49 (CH), 44.17 ( $\text{CH}_2\text{-NH}$ ), 49.24 ( $2\times\text{CH}_2\text{-N}$ ), 65.54 ( $2\times\text{CH}_2\text{-O}$ ), 66.52 ( $2\times\text{CH}_2\text{-O}$ , THP), 117.55 (q,  $J_{\text{(C,F)}} = 33.9$  Hz, C5), 120.32 (q,  $J_{\text{(C,F)}} = 272.4$  Hz,  $\text{CF}_3$ ), 124.98 (q,  $J_{\text{(C,F)}} = 5.3$  Hz, C4), 145.86 (C=N), 157.46 (C=O), 160.99 ( $\text{-N-C=N}$ ); Analysis for  $\text{C}_{16}\text{H}_{21}\text{F}_3\text{N}_4\text{O}_3$  (374), Calcd.: C, 51.33; H, 5.65; N, 14.97; Found: C, 51.46; H, 5.68; N, 14.95.

6-((2-Hydroxyethyl)amino)-5-(trifluoromethyl)-N-(2-(trifluoromethyl) benzyl)pyridazine-3-carboxamide (11n)

Yellow oil; Yield (57%);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 3.80-3.84 (m, 4H,  $2\times\text{CH}_2$ ), 4.77 (d, 2H,  $J = 6.0$  Hz,  $\text{CH}_2\text{-NH}$ ), 5.76 (brs, 1H, NH), 7.29 (t, 1H,  $J = 7.6$  Hz, C5-Ar), 7.41 (t, 1H,  $J = 7.6$  Hz, C4-Ar), 7.50 (d, 1H,  $J = 7.6$  Hz, C6-Ar), 7.57 (d, 1H,  $J = 7.6$  Hz, C3-Ar), 8.13 (s, 1H, CH-pyridazine), 8.16 (t-like, 1H,  $J = 5.2$  Hz,  $\text{NH-CO}$ ); Analysis for  $\text{C}_{16}\text{H}_{14}\text{F}_6\text{N}_4\text{O}_2$  (408), Calcd.: C, 47.07; H, 3.46; N, 13.72; Found: C, 46.92; H, 3.44; N, 13.76.

6-(Butylamino)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)benzyl)pyridazine-3-carboxamide (11o)

Yellow oil; Yield (60%);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 0.87 (t, 3H,  $J = 7.6$  Hz,  $\text{CH}_3$ ), 1.33-1.41 (m, 2H,  $\text{CH}_2$ ), 1.59-1.67 (m, 2H,  $\text{CH}_2$ ), 3.62 (q, 2H,  $J = 7.2$  Hz,  $\text{CH}_2\text{-NH}$ ), 4.78 (d, 2H,  $J = 6.4$  Hz,  $\text{CH}_2$ ), 5.17 (brs, 1H, NH), 7.29 (t, 1H,  $J = 7.6$  Hz, C5-Ar), 7.42 (t, 1H,  $J = 7.6$  Hz, C4-Ar), 7.52 (d, 1H,  $J = 8.0$  Hz, C6-Ar), 7.58 (d, 1H,  $J = 8.0$  Hz, C3-Ar), 8.12 (s, 1H, CH-pyridazine), 8.14 (t-like, 1H,  $J = 5.6$  Hz,  $\text{NH-CO}$ ); Analysis for  $\text{C}_{18}\text{H}_{18}\text{F}_6\text{N}_4\text{O}$  (420), Calcd.: C, 51.43; H, 4.32; N, 13.33; Found: C, 51.54; H, 4.30; N, 13.39.

6-((Cyclopropylmethyl)amino)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)benzyl)pyridazine-3-carboxamide (11p)

Yellow oil; Yield (61%);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 0.23 (q-like, 2H,  $J = 5.2$  Hz,  $\text{CH}_2$ ), 0.52 (q-like, 2H,  $J = 5.2$  Hz,  $\text{CH}_2$ ), 1.09-1.15 (m, 1H, CH), 3.47 (dd, 2H,  $J = 5.6, 6.4$  Hz,  $\text{CH}_2$ ), 4.78 (d, 2H,  $J = 6.4$  Hz,  $\text{CH}_2$ ), 5.28 (brs, 1H, NH), 7.29 (t, 1H,  $J = 7.6$  Hz, C5-Ar), 7.42 (t, 1H,  $J = 7.6$  Hz, C4-Ar), 7.52 (d, 1H,  $J = 7.6$  Hz, C6-Ar), 7.58 (d, 1H,  $J = 7.6$  Hz, C3-Ar), 8.13 (s, 1H, CH-pyridazine), 8.16 (t-like, 1H,  $J = 5.6$  Hz, NH-CO); Analysis for  $\text{C}_{18}\text{H}_{16}\text{F}_6\text{N}_4\text{O}$  (418), Calcd.: C, 51.68; H, 3.86; N, 13.39; Found: C, 51.59; H, 3.87; N, 13.41.

6-(Cyclopentylamino)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)benzyl)pyridazine-3-carboxamide (11q)

Yellow oil; Yield (51%);  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ , 400 MHz)  $\delta$  ppm: 1.42-1.50 (m, 2H,  $\text{CH}_2$ ), 1.58-1.71 (m, 4H,  $2\times\text{CH}_2$ ), 2.09-2.16 (m, 2H,  $\text{CH}_2$ ), 4.77 (d, 2H,  $J = 6.4$  Hz,  $\text{CH}_2\text{-NH}$ ), 5.08 (d, 1H,  $J = 5.6$  Hz, NH), 7.29 (t, 1H,  $J = 7.6$  Hz, C5-Ar), 7.42 (t, 1H,  $J = 7.6$  Hz, C4-Ar), 7.52 (d, 1H,  $J = 7.6$  Hz, C6-Ar), 7.58 (d, 1H,  $J = 7.6$  Hz, C3-Ar), 8.12 (s, 1H, CH-pyridazine), 8.14 (t-like, 1H,  $J = 5.6$  Hz, NH-CO); Analysis for  $\text{C}_{19}\text{H}_{18}\text{F}_6\text{N}_4\text{O}$  (432), Calcd.: C, 52.78; H, 4.20; N, 12.96; Found: C, 52.90; H, 4.16; N, 12.94.

6-Morpholino-5-(trifluoromethyl)-N-(2-(trifluoromethyl)benzyl)pyridazine-3-carboxamide (11r)

Yellow oil; Yield (60%);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz)  $\delta$  ppm: 3.65 (t, 4H,  $J = 4.4$  Hz,  $2\times\text{CH}_2\text{-N}$ ), 3.85 (t, 4H,  $J = 4.8$  Hz,  $2\times\text{CH}_2\text{-O}$ ), 4.87 (d, 2H,  $J = 6$  Hz,  $\text{CH}_2\text{-NH}$ ), 7.38 (t, 1H,  $J = 7.6$  Hz, C5-Ar), 7.50 (t, 1H,  $J = 8.0$  Hz, C4-Ar), 7.61 (d, 1H,  $J = 7.6$  Hz, C6-Ar), 7.67 (d, 1H,  $J = 8.0$  Hz, C3-Ar), 8.26 (t-like, 1H,  $J = 5.2$  Hz, NH-CO), 8.35 (s, 1H, CH-pyridazine); Analysis for  $\text{C}_{18}\text{H}_{16}\text{F}_6\text{N}_4\text{O}_2$  (434), Calcd.: C, 49.78; H, 3.71; N, 12.90; Found: C, 49.84; H, 3.72; N, 12.87.

## 2. Anti-proliferative activities

The three examined human cancer cell lines; T-47D (breast cancer), MDA-MB-231 (breast carcinoma) and SKOV-3 (ovarian cancer), as well as the non-tumorigenic human breast cell line (MCF-10A) have been obtained from American Type Culture Collection (ATCC). The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat inactivated fetal calf serum (GIBCO), penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37 °C in humidified atmosphere containing 5% CO<sub>2</sub>. Cells at a concentration of 0.50 x 10<sup>6</sup> were grown in a 25 cm<sup>2</sup> flask in 5 ml of culture medium.

The anti-proliferative activity of the tested pyridazines **11a-r** was measured *in vitro* using the Sulfo-Rhodamine-B stain (SRB) assay. Briefly, Cells were inoculated in 96-well microtiter plate (5X10<sup>4</sup> cells/ well) for 24 h before treatment with the tested pyridazines to allow attachment of cell to the wall of the plate. Tested pyridazines were dissolved in DMSO at 1 mg/ml immediately before use and diluted to the appropriate volume just before addition to the cell culture. Different concentrations of tested pyridazines and staurosporine were added to the cells (three wells were prepared for each individual dose). Cells were incubated with the pyridazines for 48 h at 37°C and in atmosphere of 5% CO<sub>2</sub>. After 48 h cells were fixed, washed, and stained for 30 min with 0.4% (w/v) SRB dissolved in 1% acetic acid. Unbound dye was removed by four washes with 1% acetic acid, and attached stain was recovered with Tris-EDTA buffer. Color intensity was measured in an ELISA reader. The relation between percent of surviving fraction and drug concentration is plotted to get the survival curve for each cell line. The concentration required for 50% inhibition of cell viability (IC<sub>50</sub>) was calculated.

## 3. Cell Cycle Analysis

Breast cancer T-47D and MDA-MB-231 cells were treated with pyridazines **11l** and **11m** for 24 h (at their IC<sub>50</sub> concentration), and then cells were washed twice with ice-cold phosphate buffered saline (PBS). Subsequently, the treated cells were collected by centrifugation, fixed in ice-cold 70% (v/v) ethanol, washed with PBS, re-suspended with 100 µg/mL RNase, stained with 40 µg/mL PI, and analyzed by flow cytometry using FACS Calibur (Becton Dickinson, BD, Franklin Lakes, NJ, USA). The cell cycle distributions were calculated using CellQuest software 5.1 (Becton Dickinson).

#### 4. Annexin V-FITC Apoptosis Assay

Phosphatidylserine externalization was assayed using Annexin V-FITC/PI apoptosis detection kit (BD Biosciences, USA) according to the manufacturer's instructions. Breast cancer T-47D and MDA-MB-231 cells were cultured to a monolayer then treated with pyridazines **11l** and **11m** at their IC<sub>50</sub> concentration. Briefly, cells were then harvested *via* trypsinization, and rinsed twice in PBS followed by binding buffer. Moreover, cells were re-suspended in 100 µL of binding buffer with the addition of 1 µL of FITC-Annexin V followed by an incubation period of 30 min at 4 °C. Cells were then rinsed in binding buffer and resuspended in 150 µL of binding buffer with the addition of 1 µL of DAPI (1 µg/µL in PBS). Cells were then analyzed using the flow cytometer BD FACS Canto II and the results were interpreted with FlowJo7.6.4 software (Tree Star, Ashland, OR, USA).

#### 5. CDK Kinase Inhibitory Activity

The CDK2 enzyme inhibitory activity was determined for pyridazines **11e**, **11h**, **11l**, and **11m** using the CDK2/CyclinA2 Kinase Enzyme System (catalog No. V2971) (Promega, Milan, Italy), according to the manufacturer's instructions.

#### 6. Statistical Analysis

Data are presented as means ± S.D. Individual groups were compared using the two-tailed independent Student's *t*-test. Multiple group comparisons were carried out using one-way analysis of variance (ANOVA) followed by the Tukey–Kramer test for post-hoc analysis. Statistical significance was accepted at a level of  $p < 0.05$ . All statistical analyses were performed using GraphPad InStat software, version 3.05 (GraphPad Software, Inc., La Jolla, CA, USA). Graphs were sketched using GraphPad Prism software, version 5.00 (GraphPad Software, Inc., La Jolla, CA, USA).




Figure S1. Different target classes suggested by SwissTargetPrediction online tool (for compound 5J), showing the protein kinases as the most probable targets

# SwissTargetPrediction

Target	Common name	Uniprot ID	ChEMBL ID	Target Class	Probability*	Known actives (3D/2D)
Pyruvate dehydrogenase kinase isoform 2	PDK2	Q15119	CHEMBL3861	Kinase	0.104671941128	131 / 0
MAP kinase signal-integrating kinase 2	MKMK2	Q9HBH9	CHEMBL4204	Kinase	0.104671941128	1 / 0
Tyrosine-protein kinase JAK1	JAK1	P23458	CHEMBL2835	Kinase	0.104671941128	78 / 0
Tyrosine-protein kinase JAK2	JAK2	O60674	CHEMBL2971	Kinase	0.104671941128	87 / 0
Leucine-rich repeat serine/threonine-protein kinase 2	LRRK2	Q5S007	CHEMBL1075104	Kinase	0.104671941128	88 / 0
Cyclin-dependent kinase 1/cyclin B	CCNB3 CDK1 CCNB1 CCNB2	Q8WWL7 P06493 P14635 O95067	CHEMBL2094127	Other cytosolic protein	0.104671941128	4 / 0
Cyclin-dependent kinase 2/cyclin A	CDK2 CCNA1 CCNA2	P24941 P78396 P20248	CHEMBL2094128	Other cytosolic protein	0.104671941128	1 / 0
Acyl-CoA desaturase	SCD	O00767	CHEMBL5555	Enzyme	0.104671941128	19 / 110
Tyrosine-protein kinase SRC	SRC	P12931	CHEMBL267	Kinase	0.104671941128	10 / 0
Tyrosine-protein kinase ZAP-70	ZAP70	P43403	CHEMBL2803	Kinase	0.104671941128	6 / 0
Sodium channel protein type X alpha subunit (by homology)	SCN10A	Q9Y5Y9	CHEMBL5451	Voltage-gated ion channel	0.104671941128	4 / 0
Glutamate NMDA receptor; GRIN1/GRIN2A	GRIN2A GRIN1	Q12879 Q05586	CHEMBL1907604	Ligand-gated ion channel	0.104671941128	3 / 0
Glutamate receptor ionotropic, AMPA 2	GRIA2	P42262	CHEMBL4016	Ligand-gated ion channel	0.104671941128	19 / 0
PI3-kinase p110-alpha subunit	PIK3CA	P42336	CHEMBL4005	Enzyme	0.104671941128	51 / 0
Protein-tyrosine phosphatase 1B	PTPN1	P18031	CHEMBL335	Phosphatase	0.104671941128	27 / 0
T-cell protein-tyrosine phosphatase	PTPN2	P17706	CHEMBL3807	Phosphatase	0.104671941128	16 / 0
Serine/threonine-protein kinase AKT	AKT1	P31749	CHEMBL4282	Kinase	0.104671941128	21 / 0
HERG	KCNH2	Q12809	CHEMBL240	Voltage-gated ion channel	0.104671941128	87 / 0
Inhibitor of nuclear factor kappa B kinase epsilon subunit	IKBKE	Q14164	CHEMBL3529	Kinase	0.104671941128	1 / 0
Arachidonate 5-lipoxygenase	ALOX5	P09917	CHEMBL215	Oxidoreductase	0.104671941128	6 / 0
LXR-alpha	NR1H3	Q13133	CHEMBL2808	Nuclear receptor	0.104671941128	66 / 0
LXR-beta	NR1H2	P55055	CHEMBL4093	Nuclear receptor	0.104671941128	78 / 0



Target	Common name	Uniprot ID	ChEMBL ID	Target Class	Probability*	Known actives (3D/2D)
Cyclin-dependent kinase 2	CDK2	P24941	CHEMBL301	Kinase	0.104671941128	18 / 0
Cyclin-dependent kinase 1	CDK1	P06493	CHEMBL308	Kinase	0.104671941128	15 / 0
P2X purinoceptor 7	P2RX7	Q99572	CHEMBL4805	Ligand-gated ion channel	0.104671941128	21 / 0
GABA receptor alpha-5 subunit	GABRA5	P31644	CHEMBL5112	Ligand-gated ion channel	0.104671941128	20 / 0
MAP kinase ERK2	MAPK1	P28482	CHEMBL4040	Kinase	0.104671941128	9 / 0
Microtubule-associated protein 2	MAP2	P11137	CHEMBL2390810	Unclassified protein	0.104671941128	10 / 0
Cathepsin K	CTSK	P43235	CHEMBL268	Protease	0.104671941128	15 / 0
Cathepsin S	CTSS	P25774	CHEMBL2954	Protease	0.104671941128	12 / 0
Cholesteryl ester transfer protein	CETP	P11597	CHEMBL3572	Other ion channel	0.104671941128	61 / 0
11-beta-hydroxysteroid dehydrogenase 1	HSD11B1	P28845	CHEMBL4235	Enzyme	0.104671941128	88 / 0
Sodium channel protein type IX alpha subunit	SCN9A	Q15858	CHEMBL4296	Voltage-gated ion channel	0.104671941128	66 / 0
Hormone sensitive lipase	LIPE	Q05469	CHEMBL3590	Enzyme	0.104671941128	25 / 0
Vanilloid receptor	TRPV1	Q8NER1	CHEMBL4794	Voltage-gated ion channel	0.104671941128	268 / 0
Fibroblast growth factor receptor 3	FGFR3	P22607	CHEMBL2742	Kinase	0.104671941128	32 / 0
15-hydroxyprostaglandin dehydrogenase [NAD <sup>+</sup> ]	HPGD	P15428	CHEMBL1293255	Enzyme	0.104671941128	3 / 0
ADAM17	ADAM17	P78536	CHEMBL3706	Protease	0.104671941128	7 / 0
Signal transducer and activator of transcription 3	STAT3	P40763	CHEMBL4026	Transcription factor	0.104671941128	1 / 0
Dihydroorotate dehydrogenase	DHODH	Q02127	CHEMBL1966	Oxidoreductase	0.104671941128	7 / 0
Beta-glucocerebrosidase	GBA	P04062	CHEMBL2179	Enzyme	0.104671941128	1 / 0
Epoxide hydratase	EPHX2	P34913	CHEMBL2409	Protease	0.104671941128	29 / 0
Sodium channel protein type V alpha subunit	SCN5A	Q14524	CHEMBL1980	Voltage-gated ion channel	0.0	5 / 0
Tyrosine kinase non-receptor protein 2	TNK2	Q07912	CHEMBL4599	Kinase	0.0	1 / 0
5-lipoxygenase activating protein	ALOX5AP	P20292	CHEMBL4550	Other cytosolic protein	0.0	16 / 0
Beta-secretase 1	BACE1	P56817	CHEMBL4822	Protease	0.0	78 / 0
Diacylglycerol O-acyltransferase 1	DGAT1	O75907	CHEMBL6009	Enzyme	0.0	14 / 0
Thrombin and coagulation factor X	F10	P00742	CHEMBL244	Protease	0.0	97 / 0



Target	Common name	Uniprot ID	ChEMBL ID	Target Class	Probability*	Known actives (3D/2D)
Probable G-protein coupled receptor 52	GPR52	Q9Y2T5	CHEMBL3297639	Family A G protein-coupled receptor	0.0	11 / 0
Cathepsin L	CTSL	P07711	CHEMBL3837	Protease	0.0	1 / 0
Phosphodiesterase 5A	PDE5A	O76074	CHEMBL1827	Phosphodiesterase	0.0	21 / 0
Mitogen-activated protein kinase kinase kinase 12	MAP3K12	Q12852	CHEMBL1908389	Enzyme	0.0	62 / 0
Glucagon-like peptide 1 receptor	GLP1R	P43220	CHEMBL1784	Family B G protein-coupled receptor	0.0	3 / 0
Glucagon receptor	GCGR	P47871	CHEMBL1985	Family B G protein-coupled receptor	0.0	10 / 0
Glucocorticoid receptor	NR3C1	P04150	CHEMBL2034	Nuclear receptor	0.0	25 / 0
Fibroblast growth factor receptor 1	FGFR1	P11362	CHEMBL3650	Kinase	0.0	2 / 0
Monocarboxylate transporter 1	SLC16A1	P53985	CHEMBL4360	Electrochemical transporter	0.0	6 / 0
Gastric inhibitory polypeptide receptor	GIPR	P48546	CHEMBL4383	Family B G protein-coupled receptor	0.0	5 / 0
Anandamide amidohydrolase	FAAH	O00519	CHEMBL2243	Enzyme	0.0	19 / 0
Serine/threonine-protein kinase AKT2	AKT2	P31751	CHEMBL2431	Kinase	0.0	5 / 0
Serine/threonine-protein kinase AKT	AKT3	Q9Y243	CHEMBL4816	Kinase	0.0	5 / 0
Transient receptor potential cation channel subfamily M member 8	TRPM8	Q7Z2W7	CHEMBL1075319	Voltage-gated ion channel	0.0	26 / 0
Integrin alpha-4/beta-1	ITGB1 ITGA4	P05556 P13612	CHEMBL1907599	Membrane receptor	0.0	9 / 0
Liver glycogen phosphorylase	PYGL	P06737	CHEMBL2568	Enzyme	0.0	3 / 0
Serine/threonine-protein kinase PIM1	PIM1	P11309	CHEMBL2147	Kinase	0.0	9 / 0
Peroxisome proliferator-activated receptor gamma	PPARG	P37231	CHEMBL235	Nuclear receptor	0.0	66 / 0
Peroxisome proliferator-activated receptor alpha	PPARA	Q07869	CHEMBL239	Nuclear receptor	0.0	17 / 0
Serine/threonine-protein kinase PIM2	PIM2	Q9P1W9	CHEMBL4523	Kinase	0.0	7 / 0
Phosphodiesterase 10A (by homology)	PDE10A	Q9Y233	CHEMBL4409	Phosphodiesterase	0.0	16 / 0
Receptor protein-tyrosine kinase erbB-2	ERBB2	P04626	CHEMBL1824	Kinase	0.0	15 / 0
Nerve growth factor receptor Trk-A	NTRK1	P04629	CHEMBL2815	Kinase	0.0	30 / 0
Neurokinin 1 receptor	TACR1	P25103	CHEMBL249	Family A G protein-coupled receptor	0.0	155 / 0






Target	Common name	Uniprot ID	ChEMBL ID	Target Class	Probability*	Known actives (3D/2D)
Tyrosine-protein kinase ABL (by homology)	ABL1	P00519	CHEMBL1862	Kinase	0.0	10 / 0
Cyclin T1	CCNT1	O60563	CHEMBL2108	Other cytosolic protein	0.0	6 / 0
Thymidine kinase, mitochondrial	TK2	O00142	CHEMBL4580	Enzyme	0.0	1 / 0
Serine/threonine-protein kinase B-raf	BRAF	P15056	CHEMBL5145	Kinase	0.0	43 / 0
Glucokinase regulatory protein	GCKR	Q14397	CHEMBL1075152	Enzyme	0.0	25 / 0
Histone deacetylase 3	HDAC3	O15379	CHEMBL1829	Eraser	0.0	2 / 0
Cyclin-dependent kinase 2/cyclin E1	CCNE1 CDK2	P24864 P24941	CHEMBL1907605	Kinase	0.0	3 / 0
CDK3/Cyclin E	CCNE1 CDK3	P24864 Q00526	CHEMBL3038471	Kinase	0.0	3 / 0
Inhibitor of nuclear factor kappa B kinase beta subunit	IKBKB	O14920	CHEMBL1991	Kinase	0.0	2 / 0
c-Jun N-terminal kinase 3	MAPK10	P53779	CHEMBL2637	Kinase	0.0	8 / 0
Inhibitor of NF-kappa-B kinase (IKK)	CHUK	O15111	CHEMBL3476	Kinase	0.0	2 / 0
2-acylglycerol O-acyltransferase 2	MOGAT2	Q3SYC2	CHEMBL2439944	Transferase	0.0	5 / 0
Kinesin-like protein 1	KIF11	P52732	CHEMBL4581	Other cytosolic protein	0.0	2 / 0
Sodium/glucose cotransporter 1	SLC5A1	P13866	CHEMBL4979	Electrochemical transporter	0.0	136 / 0
Hepatocyte growth factor receptor	MET	P08581	CHEMBL3717	Kinase	0.0	12 / 0
Focal adhesion kinase 1	PTK2	Q05397	CHEMBL2695	Kinase	0.0	21 / 0
Mitogen-activated protein kinase kinase kinase 14	MAP3K14	Q99558	CHEMBL5888	Kinase	0.0	22 / 0
Tyrosine-protein kinase JAK3	JAK3	P52333	CHEMBL2148	Kinase	0.0	11 / 0
Cannabinoid receptor 1 (by homology)	CNR1	P21554	CHEMBL218	Family A G protein-coupled receptor	0.0	17 / 0
Cannabinoid receptor 2	CNR2	P34972	CHEMBL253	Family A G protein-coupled receptor	0.0	27 / 0
PI3-kinase p110-delta subunit	PIK3CD	O00329	CHEMBL3130	Enzyme	0.0	29 / 0
PI3-kinase p110-beta subunit	PIK3CB	P42338	CHEMBL3145	Enzyme	0.0	27 / 0
Androgen Receptor (by homology)	AR	P10275	CHEMBL1871	Nuclear receptor	0.0	76 / 0
Metabotropic glutamate receptor 2 (by homology)	GRM2	Q14416	CHEMBL5137	Family C G protein-coupled receptor	0.0	8 / 0



Target	Common name	Uniprot ID	ChEMBL ID	Target Class	Probability*	Known actives (3D/2D)
Interleukin-8 receptor B	CXCR2	P25025	CHEMBL2434	Family A G protein-coupled receptor	0.0	2 / 0
Fructose-1,6-bisphosphatase	FBP1	P09467	CHEMBL3975	Enzyme	0.0	9 / 0
Interleukin-8 receptor A	CXCR1	P25024	CHEMBL4029	Family A G protein-coupled receptor	0.0	2 / 0
Vasopressin V2 receptor	AVPR2	P30518	CHEMBL1790	Family A G protein-coupled receptor	0.0	3 / 0









































**11a**











11a















































































































11n

